GlassScriptPhysician profile
Paul J Park
NPI 1295140309
$2,213.23
in general payments reported to CMS, 2019-2025
22 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $270 · 2021: $524 · 2022: $340 · 2023: $175 · 2024: $313 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $470.01 | 2019-2021 | |
| Abbvie INC. | $217.02 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $190.61 | 2019-2025 | Cequa |
| Allergan, INC. | $178.61 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $170.62 | 2019-2023 | |
| Stryker Corporation | $167.25 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.04 | 2019-2020 | |
| Genentech USA, INC. | $93.31 | 2022-2024 | Vabysmo |
| Bausch & Lomb Americas INC. | $80.09 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Amgen INC. | $63.91 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $62.78 | 2024 | |
| Abb Con-Cise Optical Group LLC | $61.84 | 2024 | Contact Lens, Spectacle Lenses |
| Alcon Vision LLC | $59.66 | 2019-2025 | Rocklatan, Hydrus Microstent |
| Horizon Therapeutics Plc | $53.70 | 2022-2023 | Tepezza |
| Dompe US, INC. | $46.50 | 2024-2025 | Oxervate |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Thea Pharma INC. | $32.53 | 2022-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $31.44 | 2024 | Xdemvy |
| Harrow Eye, LLC | $28.25 | 2025 | Triesence |
| Sight Sciences, INC. | $18.52 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Shire North American Group INC | $17.33 | 2019 | |
| Mallinckrodt Hospital Products INC. | $15.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.